CN118785917A - 治疗性肽的用途 - Google Patents

治疗性肽的用途 Download PDF

Info

Publication number
CN118785917A
CN118785917A CN202280091621.8A CN202280091621A CN118785917A CN 118785917 A CN118785917 A CN 118785917A CN 202280091621 A CN202280091621 A CN 202280091621A CN 118785917 A CN118785917 A CN 118785917A
Authority
CN
China
Prior art keywords
subject
peptide
pharmaceutically acceptable
acceptable salt
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280091621.8A
Other languages
English (en)
Chinese (zh)
Inventor
I·格拉切夫
S·黄
T·柯达
H·穆尔克
西田隆志
大晌幸作
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Weige Treatment Co ltd
Original Assignee
Kyoto University NUC
Weige Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC, Weige Treatment Co ltd filed Critical Kyoto University NUC
Publication of CN118785917A publication Critical patent/CN118785917A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202280091621.8A 2021-12-15 2022-12-14 治疗性肽的用途 Pending CN118785917A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163289915P 2021-12-15 2021-12-15
US63/289,915 2021-12-15
PCT/US2022/081558 WO2023114846A1 (en) 2021-12-15 2022-12-14 Uses of therapeutic peptides

Publications (1)

Publication Number Publication Date
CN118785917A true CN118785917A (zh) 2024-10-15

Family

ID=85157076

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280091621.8A Pending CN118785917A (zh) 2021-12-15 2022-12-14 治疗性肽的用途

Country Status (5)

Country Link
US (1) US20250059233A1 (https=)
EP (1) EP4447987A1 (https=)
JP (1) JP2024546989A (https=)
CN (1) CN118785917A (https=)
WO (1) WO2023114846A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280202B2 (en) * 2015-03-02 2019-05-07 Kyoto University Peptide
WO2018047852A1 (en) 2016-09-07 2018-03-15 Kyoto University Peptides and peptide conjugates for treating mental disorders
WO2021100614A1 (ja) * 2019-11-19 2021-05-27 国立大学法人京都大学 大豆ペプチド及び／又はコラーゲンペプチド含有神経心理学的機能改善剤
JP7787424B2 (ja) * 2021-02-04 2025-12-17 ユーハ味覚糖株式会社 デプレスタチン含有組成物の製造方法
JPWO2022186015A1 (https=) * 2021-03-02 2022-09-09
WO2022202985A1 (ja) * 2021-03-24 2022-09-29 森永乳業株式会社 ペプチド、及び該ペプチドを有効成分として含有する組成物

Also Published As

Publication number Publication date
US20250059233A1 (en) 2025-02-20
JP2024546989A (ja) 2024-12-26
EP4447987A1 (en) 2024-10-23
WO2023114846A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
Zieglgänsberger et al. Understanding neuropathic pain
JP2014098018A (ja) Ｎｍｄａｎｒ２ｂ−サブタイプ選択的アンタゴニストを使用する障害の処置方法
US20160058830A1 (en) Therapy and Prevention of Problem Drinking
Montgomery et al. The use of cholecystokinin in schizophrenia: a review
JP2021519349A (ja) 幻覚とそれに関連する病態の治療のための方法および組成物
JP7061764B2 (ja) 精神疾患を治療するためのペプチドおよびペプチドコンジュゲート
CN118785917A (zh) 治疗性肽的用途
KR101179340B1 (ko) 우르소데옥시콜린산 및 은행잎 추출물을 포함하는 알츠하이머병의 예방 및 치료용 조성물
CN119095593A (zh) 精神作用药物及其用于治疗精神和神经病状和病症的用途
JP2025541312A (ja) Ａｖｐｒ１ａアゴニストの用途
Liotta et al. Drug-induced parkinsonism: too many cooks in the kitchen
Camarasa et al. Memory impairment induced by amphetamine derivatives in laboratory animals and in humans: a review.
TW202513053A (zh) 精神作用醫藥及其用於治療精神及神經病狀及病症之用途
EP4724433A2 (en) Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
Zhang et al. Anti-dementia Medications: Specific Agents
KR20260053276A (ko) 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도
Daly et al. Cholinesterase inhibitors for behavioral disturbance in dementia
Rainer et al. P. 1.079 Data from the Vienna Transdanube Aging (VITA) Study do not support the concept of vascular depression
Jiang Disruption of the Interaction between α7 Nicotinic Acetylcholine Receptor and Glutamate N-Methyl-D-Aspartic Acid Receptor Exerts an Anti-depressive Effect
Najib et al. Eszopiclone: efficacy and safety
Alentorn et al. Pelvic dyskinesia with an outstanding response to tetrabenazine
Rabheru et al. P1-324 Does galantamine therapy in mild to moderate Alzheimer's disease improve behaviour?
Yang et al. P. 1.080 Assessment of cerebral regions associatedwith sexual arousal in depressive women before and after antidepressant treatment by using BOLD-fMRI
Kuroki et al. Ceruletide, an analog of cholecystokinin octapeptide: new perspectives on its efficacy
Tariot et al. P1-322 A multicenter, randomized, double-blind, placebo-controlled trial of valproate for agitation associated with dementia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination